Abstract:The study is aimed at exploring the effect of microribonucleic acid- (miR-) 210 on the chemosensitivity of breast cancer and its potential molecular mechanism. Cell Counting Kit-8 (CCK-8) was applied to detect the half maximal inhibitory concentration (IC50) of cisplatin (DDP) on cell, and quantitative polymerase chain reaction (qPCR) was carried out to measure the relative expression level of miR-210. The IC50 value of DDP on cells was detected via CCK-8 after downregulating the expression of miR-210 in MCF-7/DDP cells. Flow cytometry and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) confirmed the effect of themiR-210 downregulation on the apoptosis of drug-resistant MCF-7/DDP cells. Besides, the impacts of the miR-210 downregulation on apoptosis-related proteins and Janus-activated kinase- (JAK-) signal transducer and activator of transcription (STAT) signaling pathway-related proteins were examined by Western blotting. The interaction between miR-210 and the target protein was detected through luciferase activity assay, qPCR, and Western blotting. Drug-resistant MCF-7/DDP cells had significantly stronger resistance to DDP and a remarkably higher expression level of miR-210 than control parental MCF-7 cells ( p < 0.05 ). After the downregulation of the miR-210 expression, MCF-7/DDP cells had markedly reduced resistance but obviously increased sensitivity to DDP ( p < 0.05 ). MiR-210 downregulation increased the apoptosis of MCF-7/DDP cells ( p < 0.05 ). In addition, after miR-210 was knocked down, the expression level of b-cell lymphoma 2 (Bcl-2) was decreased, while the expression levels of Bcl-2-associated X protein (Bax) and cysteinyl aspartate-specific proteinase-3 (caspase-3) were increased. Besides, miR-210 was able to suppress the expression of protein inhibitor of the activated STAT 4 (PIAS4) gene by directly targeting its 3 ′ untranslated region (3 ′ UTR). The expression of miR-210 has a correlation with chemoresistance of breast cancer MCF-7 cells. MiR-210 regulates the JAK-STAT signal transduction pathway by targeting PIAS4, thus exerting an effect on breast cancer chemosensitivity.

Silencing CDR1as Enhances the Sensitivity of Breast Cancer Cells to Drug Resistance by Acting As a Mir‐7 Sponge to Down‐regulate REGγ

Inhibition of Circular RNA CDR1as Increases Chemosensitivity of 5‐fu‐resistant BC Cells Through Up‐regulating Mir‐7

Silencing CDR1as Inhibits Colorectal Cancer Progression Through Regulating Microrna-7

Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.

Effect of MiR-210 on the Chemosensitivity of Breast Cancer by Regulating JAK-STAT Signaling Pathway

Blocking of SIRT7/FOXO3a Axis by miR-152-3p Enhances Cisplatin Sensitivity in Breast Cancer

Downregulation of SOX21-AS1 Alleviated Cisplatin Resistance in Cervical Cancer Through Epithelial-Mesenchymal Transition Inhibition

miR-185-5p May Modulate the Chemosensitivity of LUSC to Cisplatin via Targeting PCDHA11: Multi-omics Analysis and Experimental Validation

MicroRNA-181a Enhances the Chemoresistance of Human Cervical Squamous Cell Carcinoma to Cisplatin by Targeting PRKCD.

miR-34b-3p-mediated regulation of STC2 and FN1 enhances chemosensitivity and inhibits proliferation in cervical cancer

Co-Suppression Of Mdr1 (Multidrug Resistence 1) And Gcs (Glucosylceramide Synthase) Restores Sensitivity To Mutidrug Resistance Breast Cancer Cells By Rna Interference (Rnai)

Microrna-137 Inhibits Tumor Growth And Sensitizes Chemosensitivity To Paclitaxel And Cisplatin In Lung Cancer

miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis

Circ_0011385 increases cisplatin resistance in breast cancer via miR-615-5psuppression

Upregulation of Microrna-181A-5p Increases the Sensitivity of HS578T Breast Cancer Cells to Cisplatin by Inducing Vitamin D Receptor-Mediated Cell Autophagy

Silencing of CXCR4 Sensitizes Triple-Negative Breast Cancer Cells to Cisplatin

Mir-135A/b Modulate Cisplatin Resistance of Human Lung Cancer Cell Line by Targeting MCL1

The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells

Modulation of CASC2/miR-21/PTEN Pathway Sensitizes Cervical Cancer to Cisplatin.

MicroRNA-218 Regulates the Chemo-Sensitivity of Cervical Cancer Cells Through Targeting Survivin.

Downregulation of exosomal miR-1273a increases cisplatin resistance of non-small cell lung cancer by upregulating the expression of syndecan binding protein